GlassScriptPhysician profile
Alexander Helfand
NPI 1639525850
$12,503.46
in general payments reported to CMS, 2019-2025
14 companies · $1,644 in 2025
The $1,644 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $76.07 · 2023: $98.01 · 2024: $11K · 2025: $1,644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,460 · Food and Beverage: $2,528 · Travel and Lodging: $2,461 · Honoraria: $1,978.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,460.00 |
| Food and Beverage | $2,528.49 |
| Travel and Lodging | $2,461.40 |
| Honoraria | $1,977.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $5,054.29 | 2024 | |
| Exelixis INC. | $2,933.20 | 2024-2025 | Cabometyx |
| F. Hoffmann-La Roche Ag | $2,339.72 | 2024 | |
| Janssen Biotech, INC. | $1,010.00 | 2025 | Erleada |
| Astrazeneca Pharmaceuticals LP | $231.88 | 2025 | Lynparza |
| Tempus Ai, INC | $213.49 | 2024 | |
| Beone Medicines USA, INC. | $166.90 | 2025 | Brukinsa, Tevimbra |
| E.R. Squibb & Sons, L.L.C. | $143.48 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $131.44 | 2024-2025 | |
| Beigene USA, INC. | $120.58 | 2024 | Brukinsa |
| Merck Sharp & Dohme LLC | $98.01 | 2023 | Welireg |
| Pfizer INC. | $22.93 | 2024 | |
| Eisai INC. | $20.18 | 2024 | |
| Pharmaessentia USA Corporation | $17.36 | 2024 | Besremi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Helfand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.